Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MindMed (NASDAQ: MNMD ) stock is getting a buzz today thanks to approval from the U.S. Food and Drug Administration (FDA). Source: luckakcul / Shutterstock.com The FDA is allowing MindMed to move forward with ...
In this article, we take a closer look at 5 penny stocks gaining ground after releasing big news today. Thanks to even more stock market uncertainty, retail traders have turned attention to daily trends, and rightfully so. The last week has seen markets pop and drop significant percentages ...
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder <legend role="h2"><span>- FDA clearance leads to first commercial</span>IND<span>for LSD, enabling initiation of Phase 2b dose-optimization trial of MM-120 in early 2022 -</...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of approval from Health Canada for medical purposes....
MindMed Enrolls First Participant in a Study of its Session Monitoring System Canada NewsWire NEW YORK , Jan. 18, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company de...
Stephen Hurst Resigns from MindMed Board of Directors PR Newswire NEW YORK , Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, ...
At the start of last year, only a few psychedelic companies were trading on the exchange markets , with Compass Pathways (NASDAQ: CMPS) and Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”) among them. However, this year saw a number of IPOs, which increased the to...
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC Canada NewsWire - Last subject completed study in late 2021 with topline results expected in early 2022 - - Results to inform design of Phase 2a study in individuals undergoing supervised opioid wit...
MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event Canada NewsWire NEW YORK , Dec. 30, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psych...
Mind Medicine (NASDAQ:MNMD) announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. Additionally, Don Gehlert, PhD will be transitioning from his role as CSO and will continue as a Senior Scientific Advisor. "We remain dedicated to advancing our pipeline a...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corpo...
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...